Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treating HR+/HER2− breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression
Winnie Yeo, Takayuki Ueno, Ching‐Hung Lin, et al.
Breast Cancer Research and Treatment (2019) Vol. 177, Iss. 3, pp. 549-559
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Impact of delayed treatment in women diagnosed with breast cancer: A population‐based study
Peh Joo Ho, Alex R. Cook, Nur Khaliesah Binte Mohamed Ri, et al.
Cancer Medicine (2020) Vol. 9, Iss. 7, pp. 2435-2444
Open Access | Times Cited: 76
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
Seock‐Ah Im, Alessandra Gennari, Y.H. Park, et al.
ESMO Open (2023) Vol. 8, Iss. 3, pp. 101541-101541
Open Access | Times Cited: 27
Overview of Breast Cancer and Implications of Overtreatment of Early-Stage Breast Cancer: An Indian Perspective
Gouri Shankar Bhattacharyya, Dinesh Chandra Doval, Chirag Desai, et al.
JCO Global Oncology (2020), Iss. 6, pp. 789-798
Open Access | Times Cited: 67
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
Y.H. Park, Elżbieta Senkus, Seock‐Ah Im, et al.
Annals of Oncology (2020) Vol. 31, Iss. 4, pp. 451-469
Open Access | Times Cited: 52
Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy
Ann H. Partridge, Samuel M. Niman, Monica Ruggeri, et al.
The Breast (2021) Vol. 59, pp. 327-338
Open Access | Times Cited: 45
Genetic Testing Enhances the Precision Diagnosis and Treatment of Breast Cancer
Ting-Lin Yang, Wenhui Li, Tao Huang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16607-16607
Open Access | Times Cited: 11
Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study
Yifei Chen, Ruyan Zhang, Ying Yan, et al.
Breast Cancer Research and Treatment (2024) Vol. 206, Iss. 3, pp. 543-550
Open Access | Times Cited: 4
Adjuvant ovarian function suppression in premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2–negative early breast cancer: a multi-center retrospective study
Weibin Lian, Liangqiang Li, Debo Chen, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Nanoparticle-Based Combination Therapy Enhances Fulvestrant Efficacy and Overcomes Tumor Resistance in ER-Positive Breast Cancer
Bozhao Li, Feilong Qi, Fei Zhu, et al.
Cancer Research (2023) Vol. 83, Iss. 17, pp. 2924-2937
Closed Access | Times Cited: 10
Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
Yen‐Shen Lu, Andrea Li Ann Wong, Hee-Jeong Kim
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 23
Quality and reporting of clinical guidelines for breast cancer treatment: A systematic review
Marta Maes‐Carballo, Luciano Mignini, Manuel Martín‐Díaz, et al.
The Breast (2020) Vol. 53, pp. 201-211
Open Access | Times Cited: 20
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
Soo Hyun Lee, Seock‐Ah Im, Gun Min Kim, et al.
Cancers (2020) Vol. 12, Iss. 11, pp. 3265-3265
Open Access | Times Cited: 18
Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions
Jieun Lee, Hyung Soon Park, Hye Sung Won, et al.
Cancer Research and Treatment (2020) Vol. 53, Iss. 2, pp. 409-423
Open Access | Times Cited: 17
First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis
Xiaoting Huang, Shen Lin, Xin Rao, et al.
Clinical Breast Cancer (2021) Vol. 21, Iss. 4, pp. e479-e488
Closed Access | Times Cited: 14
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES
Young‐Hyuck Im, Bülent Karabulut, Keun Seok Lee, et al.
Breast Cancer Research and Treatment (2021) Vol. 188, Iss. 1, pp. 77-89
Closed Access | Times Cited: 14
Different dosage forms of GnRHa with endocrine therapy in premenopausal hormone Receptor-Positive breast cancer
Jinna Lin, Yiye Ouyang, Yudong Li, et al.
JNCI Journal of the National Cancer Institute (2024)
Closed Access | Times Cited: 1
Patient‐reported outcome and survival in premenopausal hormone receptor‐positive breast cancer patients at moderate to high risk: comparing toremifene with aromatase inhibitor in a real‐world study
Yaping Yang, Fengxia Gan, Ting Luo, et al.
MedComm (2024) Vol. 5, Iss. 10
Open Access | Times Cited: 1
Soluble Factors Involved in Cancer Cell–Macrophage Interaction Promote Breast Cancer Growth
Kimihiro Yonemitsu, Yuko Miyasato, Takuya Shiota, et al.
Anticancer Research (2021) Vol. 41, Iss. 9, pp. 4249-4258
Open Access | Times Cited: 10
Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study
Rin Ogiya, Naoki Niikura, Hiraku Kumamaru, et al.
Breast Cancer Research and Treatment (2020) Vol. 184, Iss. 2, pp. 585-596
Closed Access | Times Cited: 10
Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India
Purvish M. Parikh, Gouri Shankar Bhattacharyya, Ghanshyam Biswas, et al.
South Asian Journal of Cancer (2021) Vol. 10, Iss. 04, pp. 213-219
Open Access | Times Cited: 9
Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2‐negative metastatic breast cancer
Hyehyun Jeong, Jae Ho Jeong, Jeong Eun Kim, et al.
International Journal of Cancer (2021) Vol. 149, Iss. 4, pp. 917-924
Open Access | Times Cited: 8
Major depressive symptoms in breast cancer patients with ovarian function suppression: a cross-sectional study comparing ovarian ablation and gonadotropin-releasing hormone agonists
Junhan Jiang, Junnan Xu, Li Cai, et al.
BMC Psychiatry (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 8
Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer
Wen‐Ling Kuo, Lin-Lu Tseng, Che‐Chang Chang, et al.
Diagnostics (2021) Vol. 11, Iss. 8, pp. 1460-1460
Open Access | Times Cited: 7
Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors
Shaheenah Dawood, Joanne Wing-Yan Chiu, Chiun‐Sheng Huang, et al.
Current Medical Research and Opinion (2020) Vol. 36, Iss. 8, pp. 1363-1373
Closed Access | Times Cited: 5
Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China
Yiqun Li, Hongnan Mo, Xiuwen Guan, et al.
The Breast (2021) Vol. 61, pp. 129-135
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top